Here’s to why Bellicum Inc. (BLCM) stock rises during current market trading session?

Best Drone Stocks
Best Drone Stocks

Bellicum Inc. (NASDAQ: BLCM) stock gained by 28.38% in the current market trading session. Bellicum is a pharmaceutical business in the early stages of development that aims to cure diseases via controlled cell therapies.

>> 7 Top Picks for the Post-Pandemic Economy << 

BLCM stock’ Current Development

The University of Texas MD Anderson Cancer Center and Bellicum Pharmaceuticals declared today a major option and license agreement attempting to cover certain intellectual property and technology rights linked to Bellicum’s CaspaCIDe (inducible caspase-9, or iC9) safety switch and related technologies, as well as the use of rimiducid which is an agent used to stimulate the safety switch. MD Anderson will have the possibility to include CaspaCIDe into certain cellular therapy initiatives under the terms of this agreement.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Read More

Bellicum’s CaspaCIDe safety switch could make it easier to use cell therapies in situations where cytokine release syndrome and neurotoxicity have been reported, in the search for new targets with on-target/off-tumor safety concerns, and in combination with next-generation greater potency cell therapy constructs.

Rick Fair, President, and CEO of BLCM stated,

They’re excited to broaden their CaspaCIDe partnership with MD Anderson to provide a larger range of cancer-related programmes. The switch technology, they believe, could improve the benefit/risk balance of cell treatments. They want to keep looking for ways to increase its application through external cooperation with other thought leaders in the sector.


Each option is normally expected to be exercised upon out-licensing of an MD Anderson programme that includes iC9. Bellicum will be paid upfront and will be allowed to be part of the third-party compensation given to MD Anderson. Bellicum will also get a royalty on global sales of the product in the single digits. The financial dealings are kept under wraps for the time being. Bellicum and MD Anderson have agreed to develop the first two programmes concurrently with the agreement’s execution. This deal builds on a prior one that covered CaspaCIDe’s usage in a specific MD Anderson cell therapy programme.


Please enter your comment!
Please enter your name here